Monument Therapeutics

Monument Biosciences

This biotechnology company develops disease-modifying drugs and translational biomarkers to treat Alzheimer's disease and related dementias.

MapLight Therapeutics

This company develops targeted therapeutics for patients with brain disorders including schizophrenia, autism spectrum disorder and Parkinson’s disease.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Kynexis

This clinical-stage biotechnology company develops precision therapeutics and small-molecule inhibitors to treat cognitive impairment in patients with schizophrenia and other neurological disorders.

Cerevel Therapeutics

This biopharmaceutical company develops neuroscience medicines for patients with mental and neurological conditions including schizophrenia, Parkinson's disease and epilepsy.

Neurosterix

This biopharmaceutical company develops allosteric modulator therapeutics to treat patients suffering from neurological and neuropsychiatric disorders, including schizophrenia and mood disorders.

Mindstate Design Labs

This biotechnology company develops custom psychedelic therapeutics using an artificial intelligence platform to treat mental health conditions for patients with various psychiatric disorders.

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.